Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genovate Biotechnology CoROCO:4130 -4.62%72 Gross Margin % is 34.00% as of Dec. 2025, which is 15% below its 10-year median of 39.98. GuruFocus rates ROCO:4130 with a GF Score™ of 72/100 and a GF Value™ of NT$22.20 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 732 Biotechnology companies, Genovate Biotechnology Co ranks worse than 71.99% on this metric.
Genovate Biotechnology Co (ROCO:4130) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Genovate Biotechnology Co had a gross margin of 34.00% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Genovate Biotechnology Co Gross Margin % Related Terms
Genovate Biotechnology Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4130 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Genovate Biotechnology Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovate Biotechnology Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovate Biotechnology Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Genovate Biotechnology Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Genovate Biotechnology Co (ROCO:4130) has a Gross Margin % of 34.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Genovate Biotechnology Co and its competitors. This is 15% below median its historical median of 39.98. Over the past decade, Genovate Biotechnology Co's Gross Margin % has ranged from 34.49 to 42.78. According to the industry distribution chart, Genovate Biotechnology Co ranks #527 out of 732 companies in the Biotechnology industry, placing it in the top 72%.
Is Genovate Biotechnology Co's Gross Margin % too high?
Genovate Biotechnology Co's current Gross Margin % of 34.00% is 15% below median its 10-year median of 39.98. Over the past 10 years, this metric has ranged from a low of 34.49 to a high of 42.78. The Biotechnology industry median Gross Margin % is 60.91. Genovate Biotechnology Co's value of 34.00% is 44.2% below this industry median. Based on the distribution chart, Genovate Biotechnology Co ranks #527 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genovate Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovate Biotechnology Co ranks #527 out of 732 companies for Gross Margin %. This places Genovate Biotechnology Co in the lower half of its industry. The industry median Gross Margin % is 60.91. Genovate Biotechnology Co's value of 34.00% is 44.2% below this benchmark. Historically, Genovate Biotechnology Co's own Gross Margin % has ranged from 34.49 to 42.78 over the past decade. While the company's 10-year median is 39.98 vs. the industry median of 60.91, Genovate Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genovate Biotechnology Co's current Gross Margin % of 34.00% is 44.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Genovate Biotechnology Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genovate Biotechnology Co's current Gross Margin % is 34.00%, which is 15% below median its own 10-year median of 39.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$22.20, compared to a current price of NT$26.85 — trading 20.9% above its estimated fair value. The current Gross Margin % is 34.00%, which is 15% below median its 10-year median of 39.98 and 44.2% below the Biotechnology industry median of 60.91. Genovate Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current Gross Margin % is 34.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?
Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued.
The current stock price of NT$26.85 is trading 20.9% above its estimated GF Value™ of NT$22.20.
GuruFocus considers Genovate Biotechnology Co to be Modestly Overvalued.
Key valuation signals for ROCO:4130:
Gross Margin %: 34.00% (15% below median its 10-year median of 39.98)
GF Value™: NT$22.20 vs. price of NT$26.85 (20.9% above fair value)
Industry Position: 44.2% below the Biotechnology median (#527 of 732)
No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
72GF Score
Get the complete analysis for ROCO:4130
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4130 has been successfully added to your 
